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ABSTRACT: Adamantanyl benzamide 1 was identified as a potent, P2X7R antagonist but failed to progress further due 
to poor metabolic stability. We describe the synthesis and SAR of a series of bioisosteres of benzamide 1 to explore 
improvements in the pharmacological properties of this lead. Initial efforts investigated a series of heteroaromatic bi-
oisosteres which demonstrated improved physicochemical properties but reduced P2X7R antagonism. Installation of 
bioisosteric fluorine on the adamantane bridgeheads was well tolerated and led to a series of bioisosteres with im-
proved physicochemical properties and metabolic stability. Trifluorinated benzamide 34 demonstrated optimal physico-
chemical parameters, superior metabolic stability (ten times longer than lead benzamide 1), an improved physicokinetic 
profile and proved effective in the presence of several known P2X7R polymorphisms. 
The P2X7 purinoreceptor (P2X7R) is a non-selective, 
ligand-gated cation channel ubiquitously expressed on 
many immune cells including microglial cells in the Cen-
tral Nervous System (CNS). It is up-regulated in re-
sponse to pro-inflammatory stimuli and has been impli-
cated in a number of neuroinflammatory diseases. Acti-
vation of the P2X7R by the extracellular nucleotide 
adenosine triphosphate (ATP) mediates the processing 
and release of the pro-inflammatory cytokine, interleukin 
1 (IL-1), which is involved in a variety of cellular ac-
tions, including cell proliferation, differentiation, and 
apoptosis. Additionally, pharmacological inhibition and 
genetic studies of the P2X7R have shown elimination or 
reduction of symptoms in animal models of arthritis, de-
pression, neuropathic pain, multiple sclerosis, and Alz-
heimer’s disease.1 The modulation of P2X7R activity 
through the development of P2X7R antagonists appears 
to be a viable strategy for the treatment of neuroinflam-
matory diseases. 
Numerous drug classes have been identified in the pur-
suit to discover selective P2X7R antagonists.2 Of this 
diverse library, only a handful have proceeded to clinical 
trials (Figure 1).3 Of this list, all disclosed compounds 
belong to the carboxamide class of P2X7R antagonists 
whereby an aryl group is linked to a cycloalkyl group by 
 
Figure 1. P2X7R antagonists entering clinical trials 
and adamantanyl benzamide 1.  The cycloalkyl group, 
carboxamide linker and aryl moiety are highlighted in 
green, red and blue repspectively.  *Undisclosed 
structures are speculative based on filed patents. 
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a carboxamide linker. These compounds appear to be 
evolutionary from a series of potent carboxamides first 
reported by AstraZeneca4  Unfortunately, these initial 
carboxamides (such as adamanatanyl benzamide 1) 
were reported to have low metabolic stability. Conse-
quently, we and others have comprehensively explored 
the chemical space around AstraZeneca’s adamantanyl 
benzamide series in the hope of improving the activity 
and ADMET properties of this series 
Several structure-activity relationships (SARs) studies 
have investigated altering the aryl substituents to explore 
or reduce the lipophilicity of these series resulting in 
leads such as AZD9056, CE-224,535, and speculatively 
AFC-5128.3b, 3d Large molecular mass is a consequence 
of this strategy which could impede bioavailability and 
blood-brain penetration. The amide linker has been re-
versed, substituted and replaced (such as in 
GSK1482160) with no significant improvements report-
ed. Early hit-to-lead studies have suggested that remov-
ing or flattening the adamantane to a simpler cycloal-
kane, to reduce lipophilicity and molecular weight, is det-
rimental to potency suggesting a large three-dimensional 
structure is central to potent P2X7R antagonism.5 We, 
and others,6 have confirmed this notion by substituting 
the adamantane of lead benzamide 1 with a variety of 
polycyclic cages (from cubane to carborane) and found 
that the larger polycyclic volume was crucial for P2X7R 
antagonism.3c Unfortunately, the larger polycycles also 
result in more lipophilic compounds. In fact, most of the 
potent benzamide-based P2X7R antagonists reported in 
the literature all appear to suffer from high lipophilicity - a 
consequence of having an adamantane cage. We there-
fore sought to explore whether the original adamantanyl 
benzamide structures, identified as potent P2X7R antag-
onists albeit poor drug candidates due to high lipophilici-
ty and poor metabolic stability, could be improved 
through bioisosteric strategies with the aim to develop a 
pre-clinical lead suitable for CNS studies. In this study, 
two common bioisosteric strategies were systematically 
explored - heteroaromatic replacement of the aryl ring 
and the fluorine-for-hydrogen substitution on the ada-
mantane cage. These strategies were investigated 
through the synthesis and biological evaluation of a se-
ries of bioisosteres of adamantanyl benzamide 1. Ada-
mantanyl benzamide 1 (hP2X7R pA2 8.8) was one of the 
lead benzamides identified in AstraZeneca’s HTS and 
was the basis of our previous exploration on polycycle 
alternatives.3c  As such, this investigation would provide 
further systematic data to aid in the development of a 
P2X7R pharmacophore.  Furthermore, the methoxy 
group has the potential to be used as a site for radio-
labeling in PET imaging studies as is the case for 
JNJ54173717 (Figure 1).7 
Our initial strategy looked at replacing the benzene ring 
with heteroaromatic rings, namely azabenzenes and 
diazines, which has shown to both reduce lipophilicity 
and improve metabolic stability in other applications.8 
Three regioisomers for the pyridine analogues of lead 
benzamide 1 are possible (Scheme 1). The ortho-
pyridine 2 and para-pyridine 3 analogues (with respect to 
the carboxamide) were synthesized via the same syn-
thetic sequence. In each case, the pyridinyl nitrogen of 
3,6-dichloropicolinic acid 4 and 2,5-dichloroisonicotinic 
acid 5 was exploited to regioselectively direct aromatic 
nucleophilic substitution of the desired chloride with 
methoxide in excellent yields. Amide coupling with 
 
Scheme 1. Synthesis of heteroaromatic analogues of benzamide 1.a 
 
aReaction conditions (yields in parentheses): (a) NaOMe, MeOH, sealed flask, 100 °C, 20 h; (b) (COCl)2, CH2Cl2, rt, 1 h, 
then 1-adamantanylmethylamine•HCl 8, Et3N, CH2Cl2, 17 h; (c) MeI, K2CO3, DMF, rt, 20 h; (d) LiOH, MeOH/THF/H2O, rt; (e) 
NaOMe, MeOH, sealed flask, rt, 1 h; (f) Ethyl pyruvate, AcOH, H2O2, FeSO4, H2SO4, PhMe/H2O, <0 °C, 40 min; (g) 1-
adamantanylmethylamine 8, neat, sealed tube, 120 °C, 15 h. 
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adamantanylmethylamine 8 via in situ acid chloride for-
mation generated the picolinamide 2 and isonicotina 
mide 3 analogues. The nicotinamide 9 analogue was 
synthesized from 2-chloro-5-hydroxynicotinic acid 10 
which was alkylated to form ester 11, then saponified to 
nicotinic acid 12. Finally, amide coupling to adaman-
tanylmethylamine 8 generated nicotinamide 9.  
To further explore the effect of heteroaromatic substitu-
tion on lead benzamide 1, the three possible diazine 
regioisomers were synthesized. The pyrimidine-4-
carboxamide analogue 13 was prepared from 2,5-
dichloropyrimidine 14, with the dual activation of the py-
rimidine nitrogen atoms making the desired chloride 
substitution with methoxide regioselectively easy to gen-
erate pyrimidine 15. The ester functionality of 16 was 
then installed via a Minisci-type reaction which required 
strict control of reaction time to minimize over-reaction to 
the diester.9 Saponification of ester 16 yielded the pyrim-
idinecarboxylic acid which was insoluble in most sol-
vents, making amide coupling challenging. Consequent-
ly, direct aminolysis of ester 16 with adamantanemethyl-
amine 8 was sufficient to generate pyrimidinamide-4-
carboxamide 13 for testing. The pyridazinamide 17 was 
synthesized in an identical route from 3,6-
dichloropyradazine 18 except the pyradazinecarboxylic 
acid 21 was synthetically useful in generating pyri-
dazinamide 17. Unfortunately, the pyrazinamide ana-
logue 22 could not be obtained from the same route. 
Several other synthetic means of obtaining the final dia-
zine regioisomer 22 also proved unfruitful and so the 
synthesis of the pyrazinamide analogue 22 was stalled 
until the heteroaromatic analogues available in hand 
were assessed for biological activity.  
Table 1. SAR for azabenzamide series. 
Compound LogD7.4
a IC50 (nM)
b LLE
c 
 
1 4.23 10.5 ± 3.1 3.75 
 
2 4.39 324 ± 78 2.10 
 
3 4.13 63.1 ± 9.4 3.07 
 
9 3.64 148 ± 25 3.19 
 
13 3.86 1410 ± 180 1.99 
 
17 4.04 2240 ± 190 1.61 
a Determined experimentally by HPLC. b IC50 values were 
the mean values (n >4) ± standard deviation derived from a 
dye uptake assay with THP-1 cells. c LLE = pIC50 − LogD.  
The lipophilicity of the azabenzamide series (Table 1) 
was evaluated by an experimentally-derived LogD7.4 val-
ue determined by a HPLC method.10 All analogues, ex-
cept for the 2-pyridinamide 2, were less lipophilic than 
lead benzamide 1. The azabenzamide series were then 
assessed in vitro for their ability to inhibit human P2X7R 
(hP2X7R) pore formation by using a functional dye up-
take assay in THP-1 cells.11 Unexpectedly, the entire 
azabenzamide series was less active than lead ben-
zamide 1 (IC50 10.5 nM) with the isonicotinamide ana-
logue 3 being the best of the series (IC50 63.1 nM). The 
addition of a second nitrogen into the ring to generate 
the diazine series (13 and 17) resulted in a further reduc-
tion of activity. The micromolar potency exhibited by 
these two diazines suggested that the planned pyra-
zinamide 22 was not likely worth exploring.  The Ligand-
Lipophilicity Efficiency (LLE) calculated for each of the 
azabenzamide analogues were less than the lead ben-
zamide 1 suggesting they are all less drug-like.12 The 
drastic loss in P2X7R inhibition far surpassed any bene-
fits gained by reducing the lipophilicity of lead ben-
zamide 1 through this bioisosteric manipulation. Overall, 
it was observed that altering the electronics of the ben-
zene ring of lead benzamide 1 through heteroaromatic 
substitution is detrimental to P2X7R inhibition and is not 
a viable bioisosteric strategy to apply to the benzamide 
P2X7R inhibitor series. 
Our second bioisosteric strategy investigated the intro-
duction of fluorine-for-hydrogen substitution at the 
bridgehead carbons of the adamantane cage. The highly 
electronegative fluorine atom forms strong, polar cova-
lent bonds with carbon that reduces lipophilicity and 
blocks metabolically-labile sites. Its small atomic radius 
mimics the hydrogen atom to ensure no steric bulk is 
added to the molecule. The synthesis of the fluorinated 
adamantane bioisosteres replicates the synthetic strate-
gy reported by Pfizer involving a series of oxidation and 
deoxyfluorination steps.13   
To begin, methyl adamantanecarboxylate 23 was hy-
droxylated via a nitronium ion mediated hydride abstrac-
tion in nitric and sulfuric acid.14 The subsequent hydrox-
yl-ester 24 was then subjected to deoxyfluorination to 
install the first bridgehead fluorine and then hydrolyzed 
to generate 3-fluoroadamantane-carboxylic acid 25 and 
is a divergent point of the synthesis. The 3-
fluoroadamantanecarboxylic acid 25 can be converted to 
the 3-fluoroadamantanemethylamine 26 by amidation 
with ammonia then subsequent lithium aluminum hydride 
reduction of the carboxamide. The 3-fluoroadamantane-
methylamine 26 is then coupled to the desired 2-chloro-
5-methoxybenzoic acid 27 (Supporting information) with 
PyBOP to yield the monofluorinated benzamide ana-
logue 28 in 73% yield. The procedure of oxidation (albeit 
with permanganate), deoxyfluorination and PyBOP cou-
pling was repeated to obtain the 3,5-difluoro and 3,5,7-
trifluoro analogs 33 and 34 respectively.  
A single crystal X-ray structure of trifluorinated ben-
zamide 34 was successfully obtained (S information) 
which confirms the three fluorine atoms on the bridge-
head carbons of adamantane and also illustrates the 
ortho chlorine atom sterically forcing the benzamide am-
ide bond to twist out of plane with the benzene ring (ϕ  
 4 
Scheme 2. Synthesis of fluorinated adamantanyl P2X7R analogues.a 
 
aReaction conditions (yields in parentheses): (a) HNO3, H2SO4, 4-30 °C, 2 h, then EtOAc/H2O, (NH2)2CO, 4 °C to RT, 4 h, 
76%; (b) Deoxyfluor, CHCl3, -78°C to reflux, 2 h; (c) NaOH, MeOH, Δ, 4 h; (d)(i) CDI, THF, rt, 1 h then NH4OH(aq), rt, 4 h; (ii) 
LiAlH4, THF, Δ, 21 h; (e) 2-chloro-5-methoxybenzoic acid 27, PyBOP, DIPEA, CH2Cl2, 18 h; (f)(i) KMnO4, KOH, H2O, Δ, 2-21 
h, then HCl; (ii) H2SO4, MeOH, Δ, 2h. 
39°) which several groups have speculated as being an 
important pharmacophore of the benzamide series.15 
Indeed, the synthesis to install fluorine-for-hydrogen 
substitution on the adamantane cage proved to be valu-
able with the HPLC-determined LogD7.4 values (Table 2) 
for all fluorinated analogues reported to be less than the 
lead benzamide 1 and the azabenzamide series (Table 
1). The fluorinated benzamides 28, 33, and 34 still dis-
played nanomolar activity in the hP2X7R functional as-
say and other in vitro assays. Only a small reduction in 
activity resulted from the installation of the fluorine atoms 
suggesting the fluorine-for-hydrogen substitution on the 
adamantane cage is tolerated. With reduced lipophilicity 
and comparable P2X7R activity relative to the lead ben-
zamide 1, these fluorinated benzamides exhibited much 
higher LLE values than the lead benzamide 1 suggesting 
they may be improved drug candidates.  
A molecular hybrid of the two bioisosteric studies was 
also synthesized to validate the trends observed in both 
these studies. The 3,5-difluoro isonicotinamide 39 was 
synthesized from the amide coupling of 3,5- 
difluoroadamantanemethylamine 32 and 5-chloro-2- 
methoxyisonicotinic acid 7. The isonicotinic acid 7 was
Table 2. SAR for the fluorinated adamantanylbenzamide series. 
Compound 
 Dye uptake IC50 
hP2X7R (nM)
a 
Calcium influx IC50 (nM)
b Binding affinity 
Ki (nM)
c LLE
d LogD7.4 hP2X7R mP2X7R 
 
1 4.23 10.5 ± 3.1 25.7 ± 8.7 1905 ± 905 8.5 ± 0.6 3.75 
 
28 3.27 25.1 ± 2.7 17.4 ± 2.9 1513 ± 339 21.9 ± 0.5 4.33 
 
33 2.85 30.9 ± 8.0 10.0 ± 4.0 575 ± 108 23 ± 5 4.66 
 
34 2.83 33.9 ± 11 24.5 ± 5.5 158 ± 44 32 ± 5 4.64 
 
39 2.82 234 ± 30 - - - 3.81 
a  IC50 values were the mean values (n >4) ± standard deviation derived from a dye uptake assay with THP-1 cells.  b  IC50 
values were the mean values (n > 3) ± standard deviation derived from calcium influx in HEK cells expressing hP2X7R or 
mP2X7R. c Binding affinities (Ki) were the mean values (n > 3) ± standard deviation derived from the displacement of tritium-
labeled benzamide 1-t3 in HEK cells expressing hP2X7R.    d LLE = pIC50 (from dye uptake) – LogD (from HPLC).  Details of all 
assay conditions are provided in the Supporting Information. 
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selected for the study as its azabenzamide resulted in 
the highest activity (IC50 63 nM) of the azabenzamide 
series. The two bioisosteric strategies had a synergistic 
effect on lipophilicity with the hybrid benzamide 39 pos-
sessing the lowest lipophilicity of our entire library 
(LogD7.4 2.82). Unfortunately, the loss in hP2X7R activity 
of each bioisostere also appeared to coalesce to pro-
duce a molecular hybrid with less activity (IC50 234 nM) 
than each of the individual bioisosteres 33 (IC50 30.9 nM) 
and 3 (IC50 63 nM) and much less than the lead ben-
zamide 1 (IC50 10.5 nM).  
Based on these results, fluorinated benzamides 28, 33, 
and 34 were progressed further. The hP2X7R inhibition 
activity of the lead benzamide 1 and fluorinated ben-
zamides 28, 33, and 34 were evaluated further by a cal-
cium influx assay (Table 2). In this assay, all the fluori-
nated benzamides exhibited a greater inhibitory effect 
(IC50 10-25 nM) than in the dye uptake assay (IC50 25-34 
nM).  In addition, these results were equal to or better 
than the lead benzamide 1 (IC50 26 nM). Interestingly, 
the activity of the lead benzamide 1 and all three fluori-
nated analogues 28, 33, and 34 in the mP2X7R calcium 
flux assay was particularly poor. Whilst all benzamides 
perform equally well on the hP2X7R, there appears to be 
a trend with the mP2X7R favoring the more fluorinated 
benzamides. The reduced activity of the benzamides on 
the mP2X7R was not unexpected given the adamantanyl 
benzamide series are allosteric inhibitors and so likely 
possess poor interspecies crossover.15 Nevertheless, the 
trifluorobenzamide 34 only exhibits a 6-fold drop in activi-
ty against the mP2X7R, compared to a 74-fold drop for 
the desfluorobenzamide 1, and so may be a useful 
probe in evaluating the role of the P2X7R in mouse dis-
ease models. 
The tritium radiolabeled parent benzamide (1-t3) was 
used to examine the binding affinities of the fluorinated 
benzamide analogues on membranes from human 
P2X7R HEK-transfected cells (Table 2). All fluorinated 
benzamides exhibited comparative binding affinities (22-
32 nM) to the parent benzamide (8.5 nM). There was a 
slight drop in affinity with the addition of each fluorine 
atom to the adamantane cage suggesting the adaman-
tane cage plays a critical role in binding to a hydrophobic 
pocket which is subtly disrupted, yet tolerated, with the 
addition of each electronegative fluorine atom.  
With the fluorinated bioisosteres 28, 33 and 34 demon-
strating improved drug-like properties over lead ben-
zamide 1 in pharmacological studies, they were pro-
gressed to in vitro drug metabolism studies (Table 3). 
None of the fluorinated benzamides were identified as 
potential P-gp substrates in apparent permeability stud-
ies with all compounds exhibiting similar efflux ratios.  
This is a promising result given that AZD9056, a closely-
related adamantane benzamide that failed in phase IIb 
clinical trials, is reported as being a P-gp substrate.16   
In rat liver microsome (RLM) stability studies, the addi-
tion at least 2 fluorine atoms to the adamantane cage 
was required to note any improvement in compound half-
life.  The trifluorobenzamide 34 exhibited the greatest 
stability with a half-life 6 times longer than the lead ben-
zamide 1. A similar trend is observed in the CYP profile 
studies whereby the fluorinated benzamides 28, 33 and 
34 encountered less CYP enzyme interactions (with the 
exception of CP3A4) than the lead benzamide 1 with the 
trifluorinated benzamide 34 performing the best.  Future 
studies will assess the extent of CYP3A4 inhibition at the 
lower concentrations envisaged for dosing.  The oxida-
tion  of the bridgehead carbons of adamantane is a ma-
jor metabolic pathway for adamantane17 and we specu-
late that this is the likely fate for all conventional ada-
mantanyl benzamide libraries which ultimately translates 
to poor pharmacokinetic results. Through the fluorination 
of the bridgehead carbons of the adamantane moiety, 
we have not only improved the physicochemical proper-
ties of lead benzamide 1, but also hindered the main 
metabolic pathway which has resulted in metabolically 
more stable compounds.  
Table 3. Metabolism data for fluorinated benzamides. 
 1 28 33 34  
Papp
a 
(x10-6 cm/sec) 
A-B 40.9 28.1 40.0 30.3  
B-A 23.6 34.3 54.8 44.2  
Liver microsomeb T1/2 (h) 0.13 0.08 0.30 0.78  
CYP Profilingc 
(% inhibition with 
10 M substrate) 
1A2 25.68 7.86 7.04 5.48  
2C9 74.97 32.33 -3.00 9.26  
2C19 84.43 46.91 1.50 12.90  
2D6 -47.26 -28.95 -25.29 -29.14  
3A4 84.43 88.75 89.88 89.93  
a Papp values were mean values (n=3) ± standard devia-
tion derived from bi-directional transcellular permeability 
assay using Madin-Darby canine kidney (MDCK) cells. b 
Half-lives were calculated using the gradient derived from 
plotting compound stability against time with n=3 at each 
time point. cCytochrome P450 isozyme inhibition values 
were mean (n=3) ± SEM.  Details of all assay conditions are 
provided in the Supporting Information. 
One of the major challenges that this study seeks to ad-
dress is to improve the pharmacokinetic profile of lead 
benzamide 1, which was reported to have poor bioavail-
ability following oral administration. Whilst the mono and 
difluorinated benzamides 28 and 33 respectively, exhib-
ited similar pharmacokinetics to the lead benzamide 1, 
the trifluorinated benzamide 34 displayed superior re-
sults (Table 4).  All four compounds achieved equivalent 
maximum concentrations (Cmax 4-7 mM) in the brain that 
equated to over 100 times their binding affinity (Table 2).  
However, all three fluorinated benzamides exhibited a 
higher percentage of unbound drug, in both plasma and 
brain, than lead benzamide 1.  In the brain, the distribu-
tion of benzamides increases proportional to the amount 
of fluorine atoms present on adamantane with the vol-
ume of distribution (Vd) for trifluorobenzamide 34 deter-
mined to be 3 times greater than lead benzamide 1. 
Analyzing the elimination data, we observe that trifluoro-
benzamide 34 exhibits enhanced metabolic stability over 
all other benzamides of the series [consistent with our 
RLM results (Table 3)], with a plasma and brain half-life 
(T1/2) of 3.7 and 7.9 (respectively) times longer than the 
lead benzamide 1. The improved metabolic stability of 
trifluoribenzamide 34 resulted in an improved drug expo-
sure profile (AUC) which was almost twice that of all oth-
er benzamides in the series.  
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Table 4. Pharmacokinetic data for the fluorinated benzamide series in rats.  
 1  28  33  34 
Tissue Plasma Brain  Plasma Brain  Plasma Brain  Plasma Brain 
pba (%bound) 99.21 99.73  94.03 96.91  88.46 91.50  89.53 94.51 
T1/2 (h) 0.47 0.16  0.43 0.43  0.47 0.59  1.72 1.26 
Tmax (h) 0.02 0.02  0.02 0.02  0.02 0.02  0.02 0.02 
Cmax (ng/mL) 1190 1696  1265 2422   1716 1838  1289 1464 
AUC6 (h*ng/mL) 185.97 221.46  174.99 286.32  195.53 209.02  385.01 380.46 
AUC∞(h*ng/mL) 191.79 245.91  178.42 290.73  199.49 216.77  398.64 385.56 
Cl (mL/min/kg) 86.90 67.78  93.41 57.33  83.55 76.89  41.81 43.23 
Vd (L/kg) 2.09 0.77  1.80 0.92  1.41 1.54  2.75 2.10 
a Brain and plasma protein binding values were mean (n=3) ± SEM with tissue and blood pooled from rats.  Details of all assay 
conditions are provided in the Supporting Information. 
In humans, the P2X7R is highly polymorphic with the 
current Build of the NCBI database (Build 141) reporting 
299 amino acid altering mutations in hP2X7R, of which 
11 have a minor allele frequency above 1% (defined as 
a single nucleotide polymorphism; SNP). Many studies 
are linking P2RX7R polymorphisms to various disease 
states.18 It is therefore imperative that any potential drug 
lead also be effective against disease-inducing polymor-
phisms. We explored the inhibitory potency of our tri-
fluorinated benzamide 34 lead against six functionally 
characterized hP2X7R SNPs which are known to cause 
either gain-of-function or no change in function of 
hP2X7R (Table 5). The trifluorinated benzamide 34 is 
well tolerated against these SNPs with little to no loss of 
inhibitory activity, suggesting a potential to modulate 
P2X7R activity in diseases states involving polymor-
phisms.  
Table 5. Activity of trifluorobenzamide 34 in the 
presence of hP2X7R SNPs. 
AA 
Change Frequency19 
% WT 
Function 
IC50 (nM)
a) 
1 mM ATP 100 M BzATP 
WT   49 ± 24 33 ± 6 
V76A 0.062 44%19 ND 24 ± 9 
H155T 0.439 195%19 49 ± 21 20 ± 5 
H270R 0.255 195%19 34 ± 17 52 ± 20 
A348T 0.400 >100%20 48 ± 6 30 ± 10 
T357S 0.083 41%21 ND 35 ± 12 
Q460R 0.170 73% 55 ± 4b 62 ± 16
 b 
a IC50 values were the mean values (n = 2-3 transfec-
tions) ± standard deviation derived from a dye uptake assay 
against ATP (1 mM) or BzATP (100 M) with HEK293 cells 
transiently transfected with plasmids of functional P2X7R 
SNP variants. b Plasmid contains 348T and 460R. 
We describe the synthesis, SAR and pharmacokinetic 
results of a series of azabenzamide and fluorinated ad-
amantane bioisosteres of lead benzamide 1 in an effort 
to improve the lead’s physicochemical and pharmacoki-
netic properties. Incorporation of one or two nitrogen 
atoms into the benzene ring, to generate the 
azabenzamide series, resulted in less lipophilic candi-
dates but at the expense of significantly reduced inhibi-
tion values. Incorporation of fluorine at the bridgehead 
carbons of the adamantane moiety was well tolerated 
with a slight loss of P2X7R inhibition activity yet signifi-
cantly improved physicochemical and PK properties 
compared to lead benzamide 1. The fluorinated ben-
zamide series have also provided insight into poor meta 
bolic stability of lead benzamide 1. Through the installa-
tion of fluorine on the adamantane bridgeheads, we 
have blocked the common oxidation sites of adaman-
tane and enhanced the metabolic stability of the ben-
zamide series.  The most promising candidate of this 
study is trifluorinated benzamide 34 which demonstrated 
potent P2X7R inhibition, a strong reduction in lipophilici-
ty, improved PK properties (particularly in metabolic sta-
bility and CYP profiling) and was effective across several 
polymorphs of the hP2X7R.  Future studies endeavor to 
utilize the trifluorobenzamide 34 to test the effects of 
P2X7R antagonism in pre-clinical models of CNS disor-
ders and as a suitable PET radiotracer.     
ASSOCIATED CONTENT  
Synthesis, characterization (including X-ray crystal data), 
and biological assays. This material is available free of 
charge via the Internet at http://pubs.acs.org.”  
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